Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Evidence Based Medicine
Qi WX et al. – The results indicated that doublet therapy was superior to a single third–generation cytotoxic agent for elderly patients with advanced non–small–cell lung cancer (NSCLC). The optimal dosage and schedule of platinum–based doublet should be investigated in future prospective clinical trials. Gemcitabine–based doublet could be considered for elderly patients who were not suitable for platinum–based chemotherapy.